INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Oct 30, 2015 |
Director, President Regeneron Laboratori
Trans History: 628
|
Director, President Regeneron Laboratori | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 182,818 | $11.64 | 682,818 |
| Oct 30, 2015 |
Director, President Regeneron Laboratori
Trans History: 628
|
Director, President Regeneron Laboratori | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 182,818 | -- | -- |
| Dec 19, 2005 |
Director, EVP, CSO, & Pres Regn Res Labs
Trans History: 628
|
Director, EVP, CSO, & Pres Regn Res Labs | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 182,818 | -- | 182,818 |
| Jun 14, 2005 |
Director
Trans History: 742
|
Director | Form 4 | Other acquisition or disposition (describe transaction) | 182,171 | -- | 339,396 |
| Jun 14, 2005 |
Director
Trans History: 742
|
Director | Form 4 | Other acquisition or disposition (describe transaction) | 182,171 | -- | 63,511 |
| Aug 03, 2017 |
Director, President and CSO
Trans History: 628
|
Director, President and CSO | Form 4 | Bona fide gift | 176,223 | -- | 176,223 |
| Aug 03, 2017 |
Director, President and CSO
Trans History: 628
|
Director, President and CSO | Form 4 | Bona fide gift | 176,223 | -- | 155,406 |
| Jul 21, 2017 |
Director, President and CSO
Trans History: 628
|
Director, President and CSO | Form 4 | Bona fide gift | 176,223 | -- | 323,777 |
| Jul 21, 2017 |
Director, President and CSO
Trans History: 628
|
Director, President and CSO | Form 4 | Bona fide gift | 176,223 | -- | 331,629 |
| Sep 10, 2019 |
Ten Percent Owner
Trans History: 555
|
Ten Percent Owner | Form 4 | Open market or private sale of non-derivative or derivative security | 172,904 | $281.15 | 20,550,813 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.